文献速递治疗药物监测与药物基因组学药物不良反应与药物警戒

抗癌药物药物基因组学:个体化选择与剂量管理药物反应

Pharmacogenomics of anticancer drugs: Personalising the choice and dose to manage drug response.
PubMed 文献 · Br J Clin Pharmacol · 2020-06-30

该综述总结抗癌药物药物基因组学现有知识,指出G6PD和TPMT等基因检测已常规用于预防特定药物不良反应,而CYP2D6与他莫昔芬疗效的关联因证据矛盾存在争议。作者强调需结合临床因素、合并用药及微生物组等综合解读基因组数据,以提高抗癌药物疗效与安全性的预测准确性。

要点

  • G6PD检测可预防拉布立酶诱导的红细胞溶血,TPMT检测可预防硫嘌呤类骨髓抑制。
  • CYP2D6状态与他莫昔芬疗效的关联因证据矛盾,检测实施存在差异。
  • 整合基因组、临床因素、合并用药及微生物组可提高药物反应预测准确性。

核心结论

  • 抗癌药物基因组学已使部分基因检测常规用于用药前评估,但部分基因-药物关联证据仍存争议。
  • 综合基因组、临床因素、合并用药和微生物组等多维数据,有望更准确预测抗癌药物疗效与安全性。

研究设计与样本

  • 综述总结了抗癌药物药物基因组学现有知识,讨论个体化治疗进一步发展的机会。

主要发现

  • 许多基因-药物相互作用来自候选基因和全基因组关联研究,主要关注等位基因频率>1%的常见遗传变异。
  • G6PD基因分型或表型检测用于预防拉布立酶诱导的红细胞溶血,具有临床效用。
  • TPMT检测用于预防硫嘌呤诱导的骨髓抑制,具有临床效用。
  • CYP2D6状态与他莫昔芬疗效的关联因不同来源证据矛盾而更具争议,导致检测实施存在差异。

临床怎么用

  • 使用拉布立酶前应进行G6PD基因分型或表型检测以预防溶血。
  • 使用硫嘌呤类药物前应进行TPMT检测以预防骨髓抑制。
  • 解读药物基因组学结果时需结合临床因素、合并用药及微生物组等综合评估。

局限性

  • CYP2D6与他莫昔芬疗效的关联证据矛盾,导致检测实施存在差异。
  • 基因并非独立作用,需结合临床因素、合并用药和微生物组等综合解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The field of pharmacogenomics has made great strides in oncology over the last 20 years and indeed a significant number of pre-emptive genetic tests are now routinely undertaken prior to anticancer drug administration. Many of these gene-drug interactions are the fruits of candidate gene and genome-wide association studies, which have largely focused on common genetic variants (allele frequency>1%). Examples where there is clinical utility include genotyping or phenotyping for G6PD to prevent rasburicase-induced RBC haemolysis, and TPMT to prevent thiopurine-induced bone marrow suppression. Other associations such as CYP2D6 status in determining the efficacy of tamoxifen are more controversial because of contradictory evidence from different sources, which has led to variability in the implementation of testing. As genomic technology becomes ever cheaper and more accessible, we must look to the additional data our genome can provide to explain interindividual variability in anticancer drug response. Clearly genes do not act on their own and it is therefore important to investigate genetic factors in conjunction with clinical factors, interacting concomitant drug therapies and other factors such as the microbiome, which can all affect drug disposition. Taking account of all of these factors, in conjunction with the somatic genome, is more likely to provide better predictive accuracy in determining anticancer drug response, both efficacy and safety. This review summarises the existing knowledge related to the pharmacogenomics of anticancer drugs and discusses areas of opportunity for further advances in personalisation of therapy in order to improve both drug safety and efficacy.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Carr DF, Turner RM, Pirmohamed M, et al. Pharmacogenomics of anticancer drugs: Personalising the choice and dose to manage drug response. Br J Clin Pharmacol. 2020. PMID: 32501544. doi:10.1111/bcp.14407

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。